Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Current Assets (2016 - 2025)

Historic Current Assets for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to $42.3 million.

  • Lineage Cell Therapeutics' Current Assets rose 2284.53% to $42.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.3 million, marking a year-over-year increase of 2284.53%. This contributed to the annual value of $51.0 million for FY2024, which is 3266.3% up from last year.
  • As of Q3 2025, Lineage Cell Therapeutics' Current Assets stood at $42.3 million, which was up 2284.53% from $43.8 million recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Current Assets peaked at $111.5 million during Q4 2021, and registered a low of $34.4 million during Q3 2024.
  • Its 5-year average for Current Assets is $57.3 million, with a median of $50.0 million in 2025.
  • Its Current Assets has fluctuated over the past 5 years, first surged by 15352.62% in 2021, then crashed by 4621.2% in 2022.
  • Over the past 5 years, Lineage Cell Therapeutics' Current Assets (Quarter) stood at $111.5 million in 2021, then crashed by 46.21% to $60.0 million in 2022, then tumbled by 35.93% to $38.4 million in 2023, then skyrocketed by 32.66% to $51.0 million in 2024, then fell by 17.13% to $42.3 million in 2025.
  • Its Current Assets was $42.3 million in Q3 2025, compared to $43.8 million in Q2 2025 and $50.0 million in Q1 2025.